Roche and Prothena are collaborating to co-develop antibodies for the treatment of Parkinson's Disease. Prothena's antibody for the treatment of Parkinson's disease, PRX002, targets alpha-synuclein. PRX002 is currently in preclinical development. It is expected to enter Phase 1 clinical trials in people with Parkinson's Disease in 2014. PRX002 has already been tested in various cellular and animal models of synuclein-related disease.
Synuclein proteins are found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and characterize several neurodegenerative disorders, including Parkinson's Disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies. As part of the agreement, Roche and Prothena will initiate a research collaboration focused on including incorporation of Roche's proprietary Brain Shuttle technology to increase delivery of therapeutic antibodies to the brain.
No comments:
Post a Comment